Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (29)

1

A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Degli Esposti, L. | Daperno, M. | Dovizio, M. | +8

2

Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5 : A Literature Review

enthalten in: Clinical drug investigation | 2023

von Corominas, H. | Young, D. | Cummings, J. | +4

3

Use of biologics for the management of Crohn's disease : IG-IBD technical review based on the GRADE methodology

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Bonovas, S. | Piovani, D. | Pansieri, C. | +6

4

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases : A Real-Life, Multicenter, Observational Study

enthalten in: Inflammatory bowel diseases | 2023

von Tursi, A. | Mocci, G. | Allegretta, L. | +47

ErratumIn: Inflamm Bowel Dis. 2022 Oct 3;28(10):e145. - PMID 35820045

5

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease : A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2022

von Tursi, A. | Mocci, G. | Cuomo, A. | +89

6

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease : a multicentre, randomised, double-blind, parallel-group, phase 3b trial

enthalten in: Lancet (London, England) | 2022

von Sands, B. | Irving, P. | Hoops, T. | +117

CommentIn: Lancet. 2022 Jun 11;399(10342):2169-2171. - PMID 35691307

7

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies : Randomized SERENE CD Trial Results

enthalten in: Gastroenterology | 2022

von D'Haens, G. | Sandborn, W. | Loftus, E. | +19

CommentIn: Gastroenterology. 2022 Jun;162(7):1831-1832. - PMID 35364063

8

Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis : SERENE UC Trial Results

enthalten in: Gastroenterology | 2022

von Panés, J. | Colombel, J. | D'Haens, G. | +25

9

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis : IG-IBD technical review based on the GRADE methodology

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Bonovas, S. | Pansieri, C. | Piovani, D. | +6

10

Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis : IG-IBD clinical guidelines based on the GRADE methodology

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Macaluso, F. | Orlando, A. | Papi, C. | +55